Want to see SNTI full AI Analyst Report?
Top Page
Senti Biosciences
(NASDAQ:SNTI)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.33
▼(-17.50% Downside)
Action:Reiterated
Date:07/28/26
The score is held down primarily by very weak financial performance (minimal revenue, large recurring losses, heavy cash burn, and a thin equity cushion). Technicals also point to a sustained downtrend with high volatility. Corporate events provide a partial offset due to encouraging FDA/clinical progress, but the secured convertible financing structure adds dilution/financing-risk concerns, keeping the overall score low.
Positive Factors
Regulatory clarity for SENTI-202
Regulatory feedback and RMAT/Orphan designations materially reduce development and approval uncertainty for SENTI-202. A clearer single-arm pivotal pathway can shorten timelines, lower regulatory risk, and improve the odds of registration, strengthening long-term commercialization prospects.
Negative Factors
Minimal revenue and heavy cash burn
Negligible revenue and persistent large operating losses mean the company cannot self-fund development. Ongoing cash burn necessitates serial external financing, increasing dilution risk and potentially hampering R&D investment or trial completion if capital markets tighten over the next several months.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory clarity for SENTI-202
Regulatory feedback and RMAT/Orphan designations materially reduce development and approval uncertainty for SENTI-202. A clearer single-arm pivotal pathway can shorten timelines, lower regulatory risk, and improve the odds of registration, strengthening long-term commercialization prospects.
Read all positive factors
Senti Biosciences (SNTI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.60M
Dividend YieldN/A
Average Volume (3M)299.89K
Price to Earnings (P/E)―
Beta (1Y)2.00
Revenue GrowthN/A
EPS Growth82.28%
CountryUS
Employees39
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.92
Shares Outstanding31,144,754
10 Day Avg. Volume584,382
30 Day Avg. Volume299,887
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)41.84
Price to Sales (P/S)10628.51
P/FCF Ratio-5.36
Enterprise Value/Market Cap3.32
Enterprise Value/Revenue926.40
Enterprise Value/Gross Profit-10.88
Enterprise Value/Ebitda-0.74
Forecast
1Y Price Target
$12.00Price Target Upside2900.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.04
Revenue Forecast (FY)$38.67K
Senti Biosciences Business Overview & Revenue Model
Company Description
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogr...
How the Company Makes Money
Senti Biosciences generates revenue primarily through collaboration and licensing arrangements related to its cell-therapy engineering platforms and product candidates, which may include upfront payments, research funding or cost reimbursements, m...
Senti Biosciences Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 38.00K | 22.00K | 0.00 | 1.98M | 3.29M | 2.29M |
| Gross Profit | -3.23M | -3.62M | 0.00 | 1.98M | 3.29M | 2.29M |
| EBITDA | -47.81M | -57.80M | -54.88M | -61.34M | -45.74M | -52.31M |
| Net Income | -51.55M | -61.44M | -52.79M | -71.06M | -58.21M | -55.32M |
Balance Sheet | ||||||
| Total Assets | 38.24M | 51.22M | 97.84M | 119.48M | 180.79M | 96.70M |
| Cash, Cash Equivalents and Short-Term Investments | 8.94M | 16.42M | 48.28M | 35.93M | 98.56M | 56.03M |
| Total Debt | 19.14M | 28.89M | 33.64M | 37.67M | 37.09M | 22.73M |
| Total Liabilities | 35.68M | 45.63M | 72.19M | 52.57M | 53.53M | 36.33M |
| Stockholders Equity | 2.56M | 5.59M | 25.65M | 66.91M | 127.26M | 60.38M |
Cash Flow | ||||||
| Free Cash Flow | -37.07M | -43.64M | -41.42M | -64.43M | -76.27M | -40.18M |
| Operating Cash Flow | -36.88M | -43.44M | -41.40M | -52.40M | -34.90M | -34.63M |
| Investing Cash Flow | -58.00K | -184.00K | 34.00K | 30.08M | -81.96M | -5.54M |
| Financing Cash Flow | 12.06M | 11.76M | 53.73M | 779.00K | 118.55M | 68.44M |
Senti Biosciences Technical Analysis
Negative
0.40
Price Trends
0.78
Negative
0.87
Negative
1.12
Negative
Market Momentum
-0.14
Negative
25.39
Positive
25.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNTI, the sentiment is Negative. The current price of 0.4 is below the 20-day moving average (MA) of 0.46, below the 50-day MA of 0.78, and below the 200-day MA of 1.12, indicating a bearish trend. The MACD of -0.14 indicates Negative momentum. The RSI at 25.39 is Positive, neither overbought nor oversold. The STOCH value of 25.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNTI.
Senti Biosciences Risk Analysis
Senti Biosciences disclosed 102 risk factors in its most recent earnings report. Senti Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Senti Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $19.70M | -1.32 | -64.17% | ― | -100.00% | 94.65% | |
44 Neutral | $10.60M | -0.18 | -503.79% | ― | ― | 82.28% | |
44 Neutral | $22.79M | -0.43 | -63.87% | ― | -100.00% | 21.30% | |
43 Neutral | $43.51M | -0.13 | 73.11% | ― | 6.33% | -102.63% |
* Healthcare Sector Average
SNTI
Senti Biosciences
0.35
-1.17
-76.78%
KPTI
Karyopharm Therapeutics
2.12
-1.65
-43.77%
TVRD
Tvardi Therapeutics
1.87
-22.26
-92.25%
BRNS
Barinthus Biotherapeutics
0.60
-0.54
-47.46%
Senti Biosciences Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Senti Biosciences Details New Direct Financial Obligation
Neutral
May 26, 2026
In a brief regulatory disclosure, Senti Biosciences notes that the information described in Item 1.01 of its Current Report on Form 8-K is incorporated by reference into Item 2.03. This cross-reference indicates that details about certain financin...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Senti Biosciences Advances SENTI-202 With New FDA Support
Positive
May 14, 2026
On May 14, 2026, Senti Biosciences reported first-quarter 2026 results and highlighted progress on SENTI-202, including positive FDA feedback that supports a single-arm, multi-center pivotal trial design in relapsed/refractory acute myeloid leukem...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.